TICKERNERD
Menu
PTCTPTCTHealthcare · Biotechnology

PTCT Stock Forecast: PTC Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$63
−1.04% on the day

The 14 Wall Street analysts covering PTC Therapeutics, Inc. hold a median 12-month price target of $101 — +59.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 3 Oct 2026 — in the upper half.

Market cap
$5.3B
Ticker Nerd rank
64 / 100
Median analyst target
$101
Analysts covering
14
Revenue$360.5M+101.5% y/y
Operating income$149.0M
Net income$83.5M
Free cash flow$122.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.3%
1M
−11.6%
YTD
−16.5%
1Y
+0.7%
From 52W high
−29.1%
From 52W low
+1.9%
$62
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PTC Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Value
95
Volatility
84
Revisions
83
Momentum
70
Accruals
31
Size
22
Growth
19
Issuance
18

Quality (96): The business earns solid, repeatable profits on what it owns.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26PTCTHigh $137Median $101Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12 Buy1 Hold1 Sell
Low $70Median $101High $137

The green dot is the last close — the median target sits +59.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
22 Sept 2026Cantor FitzgeraldMaintainsOverweight$130 → $137
14 Sept 2026Leerink PartnersAssumesOutperform$98
14 Aug 2026BarclaysMaintainsOverweight—
14 Aug 2026BarclaysMaintainsOverweight$120 → $122
13 Aug 2026Wells FargoMaintainsOverweight—
13 Aug 2026Wells FargoMaintainsOverweight$106 → $109
31 July 2026Morgan StanleyMaintainsOverweight$93 → $104
31 July 2026Morgan StanleyMaintainsOverweight—
31 July 2026Wells FargoMaintainsOverweight$93 → $106
31 July 2026Wells FargoMaintainsOverweight—
20 July 2026Wells FargoMaintainsOverweight$95 → $93
20 July 2026Wells FargoMaintainsOverweight—
16 July 2026Cantor FitzgeraldMaintainsOverweight$124 → $130
16 July 2026Cantor FitzgeraldMaintainsOverweight—
7 July 2026RBC CapitalMaintainsSector Perform—
9 June 2026CitigroupAssumesBuy$75 → $108
27 May 2026JefferiesUpgradeBuy—
8 May 2026RBC CapitalMaintainsSector Perform—
8 May 2026TD CowenUpgradeBuy—
8 May 2026Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PTCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, PTC Therapeutics, Inc. returned +0.7% against +16.2% for the S&P 500, dividends included.

PTCT vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26PTCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PTCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+30.2%
Analysts raising
2
Analysts cutting
1
Fundamentals

PTC Therapeutics, Inc. (PTCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.5×

Cheaper than 62% of US stocks

Price / sales
5.3×

Cheaper than 23% of US stocks

Price / book
−31.9×

Cheaper than 99% of US stocks

EV / EBITDA
35.5×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
101.5%

Higher than 93% of US stocks

Earnings growth (YoY)
101.5%

Higher than 84% of US stocks

Gross margin
94.5%

Higher than 98% of US stocks

Operating margin
41.3%

Higher than 93% of US stocks

Net margin
−3.8%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−332.5%

Higher than 5% of US stocks

Return on assets
2.5%

Higher than 62% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PTC Therapeutics, Inc. (PTCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PTC Therapeutics, Inc. has a market value of $5.3B and an enterprise value of $6.1B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 101.5% year on year.

  • Net income over the same four quarters: −$38.4M, a −3.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.58.

  • Free cash flow in the twelve months to 30 June 2026: −$332.6M.

  • Shares outstanding: 83.3M.

  • Trailing P/E: 7.5×; forward P/E: 23.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • PTC Therapeutics, Inc. employs 991 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

PTCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTCTPTC Therapeutics, Inc.$5.3B
64
COGTCogent Biosciences, Inc.$5.3B
34
CRSPCRISPR Therapeutics AG$5.3B
37
TVTXTravere Therapeutics, Inc.$5.4B
86
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
ERASErasca, Inc.$5.0B
55
ORKAOruka Therapeutics, Inc.$5.6B
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PTC Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTCT news & analysis

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 25 Sept 2026neutral

PTC Therapeutics announced that on September 25, 2026, it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). The grants are being made as part of the company's standard equity compensation program.

Why it matters — The inducement grants signal continued employee hiring and retention incentives, which are a routine matter for investors tracking the company's management and equity programs.

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PRNewsWire · 21 Sept 2026positive

PTC Therapeutics announced it has completed its previously disclosed agreement with Sangamo Therapeutics to acquire ST-920, a one-time AAV gene therapy for Fabry disease that has reached the BLA stage. The company expects to complete its Biologics License Application (BLA) submission for the therapy in Q4 2026.

Why it matters — This acquisition adds a late-stage gene therapy to PTC's pipeline, with a BLA submission expected in late 2026 that could represent a significant commercial opportunity.

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

PTC Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports that the company participated in the investor conference.

Why it matters — A PTCT watcher would care because the presentation offers investors an opportunity to hear company management discuss its business and strategy at a major healthcare investment conference.

PTC Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire · 27 Aug 2026neutral

PTC Therapeutics announced that its executives will speak at the Wells Fargo 21st Annual Healthcare Conference in September. The company did not specify further details in the provided text.

Why it matters — PTCT watchers would care because the scheduled conference participation offers management a platform to discuss the company with investors and analysts.

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PRNewsWire · 24 Aug 2026positive

PTC Therapeutics announced it will present 17 abstracts and data at the 2026 SSIEM Annual Symposium showing that Sephience (sepiapterin) provides sustained metabolic control, enables significant diet liberalization, and maintains a favorable safety profile across patient subgroups.

Why it matters — A PTCT watcher would care because the new data strengthens Sephience's clinical profile, showing broad patient benefits and real-world evidence that could support wider adoption and reimbursement prospects.

FAQ

Frequently asked questions about PTCT stock

What is the PTCT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering PTC Therapeutics, Inc. have a median 12-month price target of $101, with estimates ranging from $70 to $137. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTCT stock a buy right now?

Of the 14 analysts covering PTC Therapeutics, Inc., 12 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PTC Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTCT?

As at 3 Oct 2026, PTC Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will PTCT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +59.2% from the last close, and Ticker Nerd's factor model ranks PTC Therapeutics, Inc. 64 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTCT stock forecast for 2030?

No analyst covering PTC Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $137 over the next 12 months.

How has PTCT stock performed over the past year?

PTC Therapeutics, Inc. returned +0.7% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders.

What is the latest news on PTCT?

The most recent item we track (PRNewsWire, 25 Sept 2026): "PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". PTC Therapeutics announced that on September 25, 2026, it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). The grants are being made as part of the company's standard equity compensation program.

Company

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders. Its current portfolio includes treatments for conditions such as Duchenne muscular dystrophy, phenylketonuria, and aromatic L-amino acid decarboxylase deficiency, along with other rare neurological and metabolic diseases. The company also works on gene therapy and small-molecule programs designed to address serious unmet medical needs. PTC Therapeutics serves children and adults in the United States and international markets, and its commercial offerings are supported by a research and development pipeline aimed at expanding its rare disease franchise. Headquartered in Warren, New Jersey, PTC Therapeutics plays a specialized role in the biopharmaceutical market by concentrating on niche therapies for complex, underserved patient populations.

CEO Dr. Matthew B. Klein F.A.C.S., M.D., M.S. · 991 employees · United States · https://www.ptcbio.com